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1. Introduction 
The release and inhibition of release of melanocyte- 
stimulating hormone (MSH) from rat pituitary are un- 
der the control of two hormonal factors present in the 
hypothalamus [ 11. Both are fragments of oxytocin re- 
sulting from an enzymic degradation of this neurohy- 
pophyseal hormone [2-51. It was established that the 
chemical structure of the MSH-release-inhibiting factor 
(MSH-R-IF) isH-Pro-Leu-Gly-NH, [3,4,6], and 
more recently we reported that the pentapeptide H- 
Cys-Tyr-Ile-Gln-Asn-OH (hereafter referred to as 
releasing peptide, R-p), possesses the capacity to re- 
lease pituitary MSH and increase MSH plasma levels 
[71. 
In this communication we show that not only 
MSH-R-IF (the C-terminal tripeptide of oxytocin) 
but also H-Pro-Lys-Gly-NH,, and H-Pro-Arg-Gly- 
NH1 (the C-terminal tripeptides of lysine- and arginine- 
vasopressin, respectively), inhibit in vivo the release of 
MSH from rat pituitary. These latter peptides are less 
potent than MSH-R-IF; other analogs of MSH-R- 
IF are inactive. R-p_ is inhibited by MSH-R-IF and 
several of its analo.gs. Tocinoic acid, the ring compo- 
I 
nent of oxytocin (H-Cys-Tyr-Ile-Gln-Asn-Cys- 
* Abbreviations of amino acid derivatives and peptides are in 
accordance with the IUPAC-IUB Commission on Biochem- 
ical Nomenclature, 3. Biol. Chem. 247 (1971) 977. The 
amino acids (except glycine) had the L-confguration unless 
otherwise stated. Ail new peptides were analyzed for C, H 
and N, and the values found differed maximally by 0.3% 
from the theoretical values. The structure of the tripeptides 
was also confumed by ammo acid analysis. Pyroglu stands 
for pyroglutamic acid (2-pyrrolldone-5-carboxylic a id). 
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OH), is inactive both in the release of MSH and in 
MSH-release inhibition in the intact rat. 
2. Materials and methods 
H-Cys-Tyr-Ile-Gln-Asn-OH (R-p) and crystalline 
H-Pro-Leu-Gly-NHs - 3 Hz0 [8] (MSH-R-IF, I) 
were the same preparations as those used in earlier 
studies [3,4,7]. Tocinoic acid was supplied by Dr. 
V.J. Hruby [9], and H-Pro-Lys-Gly-NHs * 2HCl- +Ha 0 
(II) was a gift from Dr. S. Sakakibara [IO]. Z-Pro+Arg- 
(Tos)-Gly-NH* [ 1 I] was deprotected with HF [ 121; 
the HF salt was converted to H-Pro-Arg-Gly-NH2 * 
2AcOH (III), which was purified by column chromato- 
graphy on silica gel using MeOH containing 10% AcOH 
([o]g -16.1“ (c 1, H,Q)). H-DLeu-Gly-NHa *AcOH 
(mp 233-235’ dec., [cr]g -29.5” (c 1, MeOH) was 
obtained by catalytic hydrogenolysis (10% Pd-C, RT., 
MeOH containing dil. AcOH) of Z-D-Leu-Gly-NH2 
(mp 86-88”, [o];’ + 9.8’ (c 1.2, CHCls)), which 
was obtained by acylation of H-Gly-NH2 . HCl with 
Z-D-Leu-ONp in the presence of one equivalent 
EtsN. H-D-Leu-Gly-NHs was allowed to react with 
Z-Pro-ONp and the resulting Z-Pro-D-Leu-Gly-NH* 
exhibited the physical data reported by Schneider et al. 
[13]; the tripeptide was subjected to catalytic hydro- 
genolysis and purification by preparative thin-layer 
chromatography on silica gel G (90% Me0I-I) yielding 
H-Pro-D-Leu-Gly-NHs l Crystalline H-Leu-Gly-NH** 
AcOH (mp 241-242” dec., [ol]g + 28.0” (c 1, Me0I-I)) 
was obtained from Z-Leu-Gly-NHs prepared according 
to Boissonnas et al. [ 141. The dipeptide was elongated 
with Z-Pyroglu-OPcp (mp 148-149”, [cr]g -38.9” 
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Fig. 1. Inhibition of pituitary MSH release in viva by synthe- 
tic C-terminal tripeptides of mammalian neurohypophyseal 
hormones. The left bar indicates the residual pituitary MSH 
content after i,v. injection of an homogenate of stalk median 
eminence. The other 3 bars indicate the MSH content after 
injection of H-Pro-Lys-Gly-NH2 (II), H-Pro-Arg-Gly-NH2 
(III), and H-Pro-Leu-Gly-NH2 (I) (5 ng of each peptide per 
rat). 
(c 1, DMF)) in the presence of one equivalent of N- 
methylmorpholine to give crystalline Z-Pyroglu-Leu- 
Gly-NH2 (mp 2 17-2 IS”, ]q] I>” -28.2” (c 0.8, DMF)), 
which upon catalytic hydrogenation yielded crystalline 
H-Pyroglu-Ieu-Gly-NH, (mp 174-175”, [a]$‘-17.7” 
(c 0.9, MeOH)). 
The effect of tri- and dipeptides on in viva pituitary 
MSH levels was determined in male rats (1 SO-200 g) 
according to a procedure reported earlier [2-41. In 
experiments in which tocinoic acid was tested for its 
capacity to inhibit the release of MSH from the pitu- 
itary, the incubated homogenate of stalk median 
eminence [2-4] was replaced by the acid. Tocinoic 
acid was injected directly to test its effect on release 
of MSH from the pituitary. 
The effect of the various peptides on MSH plasma 
levels was studied using male rats (1 SO-200 g) pre-. 
pared the day before the experiment as described in 
[7]. All agents were injected in a volume of 0.2 ml. 
The amount of MSH released into the blood plasma 
was compared with an (w-MSH standard (a generous 
gift from Dr. S. Lande), and is expressed in ng MSH 
per ml of plasma. All these studies were carried out 
in Argentina during the winter months, when toad 
skin (Bufo arenarum) is at its highest sensitivity to 
MSH. 
Table 1 
Inhibition of MSH-release by tripeptide fragments of the 
neurohypophyseal hormones, oxytocin, lysine-vasopressin 
and arginine-vasopressin*. 
Tripep tide 
fragment 
Plasma MSH (ng/ml) 
Exp. 1 Exp. 2 Exp. 3 Average 
H-Pro-Leu- 
Gly-NH2 (I) 1.0 
H-Pro-Lys- 
Gly-NH2 (II) 1.3 
H-Pro-Arg- 
Gly-NH2 (III) 1.9 
Controls (R-p only) 3.4 
0.9 0.8 0.9 
1.0 0.9 1.1 
3.1 1.0 2.6 
3.5 4.1 3.7 
* In triplicate experiments, 20 ng of I, II, or III was injected 
into the cannulated jungular veins of untreated male rats; 
three min later 80 ng of HCys-Tyr-Ile-Gln-Asn-OH 
(R-p) was also injected into these animals. Control animals 
received R-p only. Ten min after the administration of R-p 
rats were decapitated and the plasma MSH concentration 
(ng/ml) was measured using or-MSH as standard. 
3. Results and discussion 
In an effort to assess the structural requirements 
necessary for the specific action of the MSH-R-IF (I) 
molecule, we have compared the activities of the 
synthetic C-terminal tripeptides of lysine- and arginine- 
vasopressin with that of oxytocin in inhibiting MSH 
release from male rat pituitary in vim. As can be seen 
in fig. 1, H-Pro-Lys-Gly-NH2 (II) and H-Pro-Arg- 
Gly-NH2 (III) inhibit the release of MSH, but are less 
active than equivalent doses of I. These results agree 
with our earlier finding that the enzymic degradation 
of any of the three mammalian neurohypophyseal 
hormones by a hypothalamic microsomal preparation 
from male rats yields MSH-release-inhibiting activity 
[2-41. 
In the present study we also tested di- and tripep-. 
tide analogs of MSH-R-IF, including H-Leu-Gly-NH2, 
H-D-Leu-Gly-NH2, H-Pro-D-Leu-Gly-NH2, and 
H-Pyroglu-Leu-Gly-NH, , but found them to be in- 
active. These data are in accord with our contention 
[4] that there are highly specific structural require- 
ments for the N- and C-terminal residues of the MSH- 
R-IF molecule that are critical to its activity, but 
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p OobV 
TRIPEPTIDE (q/rat) 
Fig. 2. Inhibition of pituitary MSH release by 10 and 20 ng of 
H-Pro-Leu-Gly-NHz (- : -), H-Pro-Lys-Gly-NH? (-), and 
H-Pro-Arg-Gly-NH2 (- - -) on the MSH plasma level produced 
by 80 .ng of HCys-Tyr-Ile-Gln-Am-OH preparation. The 
experiments were performed as described in the legend of 
table 1. Each point is the average of two experiments; vertical 
lines indicate standard error. 
Log dose of MSH-R-IF 
(q/rot) 
Fig. 3. Dose-response of H-Pro-Leu-Gly-NH? as an inhibitor 
of MSH release in the presence of a constant amount of H- 
Cys-Tyr-Ile-Gln-Asn-OH, the releasing peptide R-p. The 
injection of 10, 20,40 or 80 ng of H-Pro-Leu-Gly-NH? was 
followed 3 min later by an injection of 80 ng of (R-p) into 
the cannulated jungular vein of the male rat. Ten min there- 
after the animal was decapitated and the plasma was analyzed 
for MSH activity. Results of cbntrol animals, injected with 80 
ng of (R-p), are shown on the ordinate. Each point represents 
the average of three experiments; vertical lines indicate stan- 
dard error. 
that modifications in the side chain of the penultimate 
residue are tolerable, provided the L-configuration is 
retained. 
Although Bower et al. [ 151 recently reported that 
synthetic tocinoic acid (the ring component of oxy- 
tocin) inhibits MSH release from the rat pituitary in 
vitro, we have not been able to demonstrate that in 
vivo administration of tocinoic acid (lo- 100 ng) 
results in either depletion of MSH from the pituitary, 
or inhibition of the MSH-release stimulated by R-p in 
the intact rat. Likewise, tocinoic acid showed no in- 
hibitory activity in lesioned frogs [ 161. In this context, 
it should also be noted that H-Pro-Leu-Gly-NH2 
(MSH-R-IF) inhibits the release of pituitary MSH in 
both in vitro and in vivo experiments [4], as might be 
expected of a natural principle. 
We next evaluated the relative MSH-release inhibi- 
tory activity of MSH-R-IF, of H-Pro-Lys-Gly-NH* 
in a second in vivo system. Constant amounts of the 
R-p preparation were injected into rats, with and 
without the addition of one of these tripeptides; 
10 min later the animals were decapitated, and the 
MSH in the plasma was measured..The R-p prepara- 
tion was given to stimulate the release of pituitary 
MSH, and animals injected only with R-p served as 
controls. The relative reduction in MSH of animals 
Injected with both R-p and a tripeptide served as an 
index of the degree of inhibition of MSH release ex- 
erted by the tripeptide. 
The data in table 1 and fig. 2 reveal that MSH- 
R-IF is the most potent inhibitor of the pentapep- 
tide R-p, but that the other two tripeptides are also 
inhibitory. The inhibitory effect of MSH-R-IF was 
demonstrated to be dose-dependent; introduction of 
increasing amounts of the inhibitor progressively re- 
duced the plasma concentration of MSH relative to 
that of controls. Under the present experimental con- 
ditions, approx. 60 ng of MSH-R-IF reduced plas- 
ma MSH levels below detection limits (fig. 3), suggest- 
ing that no MSH, or very little, was released from the 
rat pituitary. 
When constant amounts of MSH-R-IF are injected, 
the capacity of this peptide to inhibit the release of 
MSH from the pituitary diminishes with time; these 
data are summarized in table 2. In control groups, rats 
injected with 20 ng of R-p only showed a strong eleva- 
tion of MSH plasma levels, reaching an average of 
6.6 f 0.3 ng MSH per ml plasma. In rats first injected 
with 40 ng of the MSH-R-IF and then with R-p 
either 3 or 5 min later, MSH could not be detected 
in the plasma. However, in rats receiving R-p 7 or 9 
min after the administration of MSH-R-IF, plasma 
concentrations reached 3.5 + 0.5 and 5.3 ? 0.3, 
respectively. On the basis of thesedatamost 
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Table 2 
Reduction with time of MSH-R-IF activity in viva*. 
Time of R-p Plasma MSH (ng/ml) 
administration 
(min) Exp. 1 Exp. 2 Exp. 3 Exp. 4 Average 
3 Neg. Neg. Neg. Neg. Neg. 
5 Neg.. Neg. Neg. Neg. Neg. 
7 4.6 2.5 3.3 3.6 3.5 + 0.5 
9 5.4 5.4 4.9 5.7 5.3 * 0.3 
Controls 6.5 6.5 6.8 6.6 6.6 + 0.3 
* Sixteen male rats were divided in four groups and were in- 
jected with 40 ng each of MSH-R-IF at time zero. Each 
animal was then given 20 ng of R-p 3, 5, 7 or 9 min later, 
respectively. Four additional rats served as controls, receiv- 
ing 20 ng of R-p only. Ten minutes after administration of 
R-p, the rats were decapitated and the plasma MSH (ng/ml) 
was measured. 
probable explanation for this drop in activity is a com- 
bination of enzymic degradation of MSH-R-IF in 
blood and various tissues, together with renal clear- 
ance. It has been found that MSH-R-IF can be in- 
activated by rat serum [ 171. 
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